Biagio De Angelis
Biagio De Angelis
Opbg
Verified email at opbg.net
Title
Cited by
Cited by
Year
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
A Di Stasi, B De Angelis, CM Rooney, L Zhang, A Mahendravada, ...
Blood, The Journal of the American Society of Hematology 113 (25), 6392-6402, 2009
3702009
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia
C Quintarelli, G Dotti, B De Angelis, V Hoyos, M Mims, L Luciano, ...
Blood, The Journal of the American Society of Hematology 112 (5), 1876-1885, 2008
1312008
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells
C Quintarelli, G Dotti, ST Hasan, B De Angelis, V Hoyos, S Errichiello, ...
Blood 117 (12), 3353-3362, 2011
862011
Generation of Epstein-Barr virus–specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)
B De Angelis, G Dotti, C Quintarelli, LE Huye, L Zhang, M Zhang, F Pane, ...
Blood 114 (23), 4784-4791, 2009
772009
Interleukin 15 Provides Relief to CTLs from Regulatory T Cell–Mediated Inhibition: Implications for Adoptive T Cell–Based Therapies for Lymphoma
SK Perna, B De Angelis, D Pagliara, ST Hasan, L Zhang, ...
Clinical Cancer Research 19 (1), 106-117, 2013
662013
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma
C Quintarelli, D Orlando, I Boffa, M Guercio, VA Polito, A Petretto, ...
Oncoimmunology 7 (6), e1433518, 2018
392018
Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor
A Bertaina, A Zorzoli, A Petretto, G Barbarito, E Inglese, P Merli, ...
Oncoimmunology 6 (2), e1216291, 2017
312017
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia
C Quintarelli, B De Angelis, S Errichiello, S Caruso, N Esposito, I Colavita, ...
Leukemia research 38 (2), 236-242, 2014
242014
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model
P Bocca, E Di Carlo, I Caruana, L Emionite, M Cilli, B De Angelis, ...
Oncoimmunology 7 (1), e1378843, 2018
222018
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate
G Alimena, M Breccia, L Luciano, F Quarantelli, D Diverio, B Izzo, ...
Leukemia research 32 (2), 255-261, 2008
192008
Adoptive immunotherapy using PRAME-specific T cells in medulloblastoma
D Orlando, E Miele, B De Angelis, M Guercio, I Boffa, M Sinibaldi, A Po, ...
Cancer research 78 (12), 3337-3349, 2018
182018
Human CAR NK cells: A new non-viral method allowing high efficient transfection and strong tumor cell killing
T Ingegnere, FR Mariotti, A Pelosi, C Quintarelli, B De Angelis, N Tumino, ...
Frontiers in immunology 10, 957, 2019
162019
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia
C Quintarelli, S Sivori, S Caruso, S Carlomagno, M Falco, I Boffa, ...
Leukemia 34 (4), 1102-1115, 2020
122020
Universal ready-to-use immunotherapeutic approach for the treatment of cancer: expanded and activated polyclonal γδ memory T cells.
VA Polito, R Cristantielli, G Weber, F Del Bufalo, T Belardinilli, CM Arnone, ...
Frontiers in immunology 10, 2717, 2019
72019
Overcoming challenges in CAR T-cell product CGMP release
C Quintarelli, F Locatelli, I Caruana, B De Angelis
Molecular Therapy 24 (5), 845-846, 2016
72016
WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene
G Montano, K Vidovic, C Palladino, E Cesaro, G Sodaro, C Quintarelli, ...
Oncotarget 6 (29), 28223, 2015
72015
Gene therapy to improve migration of T cells to the tumor site
A Di Stasi, B De Angelis, B Savoldo
Immunotherapy of Cancer, 103-118, 2010
52010
CD19 redirected CAR NK cells are equally effective but less toxic than CAR T cells
C Quintarelli, S Sivori, S Caruso, S Carlomagno, I Boffa, D Orlando, ...
Blood 132 (Supplement 1), 3491-3491, 2018
42018
High-avidity cytotoxic-T-lymphocytes specific for a new preferentially expressed antigen of melanoma (PRAME)-derived peptide can target leukemic-and leukemic-precursor cells
C Quintarelli, G Dotti, ST Hasan, B De Angelis, V Hoyos, S Errichiello, ...
Blood 117, 3353-3362, 2011
42011
CD28. OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR. CD30 T-cells
M Guercio, D Orlando, S Di Cecca, M Sinibaldi, I Boffa, S Caruso, ...
Haematologica, 2020
32020
The system can't perform the operation now. Try again later.
Articles 1–20